← FDA DRUG APPROVALS

FDA ANDA · ANDA217892

POTASSIUM PHOSPHATES

Sponsor: CIPLA

APPLICATION
ANDA217892
TYPE
ANDA
ORIGINAL APPROVAL
2025-01-24
LATEST ACTION
2025-01-24
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

POTASSIUM PHOSPHATESPrescription
POTASSIUM PHOSPHATE, DIBASIC 11.8GM/50ML (236MG/ML), POTASSIUM PHOSPHATE, MONOBASIC 11.2GM/50ML (224MG/ML) · SOLUTION · INTRAVENOUS
POTASSIUM PHOSPHATESPrescription
POTASSIUM PHOSPHATE, DIBASIC 1.18GM/5ML (236MG/ML), POTASSIUM PHOSPHATE, MONOBASIC 1.12GM/5ML (224MG/ML) · SOLUTION · INTRAVENOUS
POTASSIUM PHOSPHATESPrescription
POTASSIUM PHOSPHATE, DIBASIC 3.54GM/15ML (236MG/ML), POTASSIUM PHOSPHATE, MONOBASIC 3.36GM/15ML (224MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2025-01-24UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →